TRVN - Trevena Inc logo

Trevena Inc

TRVN

Trevena, Inc. develops and commercializes novel biopharmaceuticals targeting central nervous system disorders. Key products include OLINVYK for acute pain management and investigational drugs for chronic pain and opioid use disorder.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Score
Net Growth15.52%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-82.53%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.2
Net Growth-36.85%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth17x
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth31.52%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend40%
Revenue Consistency
All Time
Scoreโ€”
Net Growth31.52%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend40%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Trevena Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. TRVN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.00โ€”
1 Year2025-10-23
$ 0.01-95.83%
5 Years2021-10-22
$ 687.50-100.00%
10 Years2016-10-21
$ 3.68K-100.00%
All Time2014-01-31
$ 4.06K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 546K-$ 34M$ 13M
2023$ 3M-$ 40M$ 32M
2022-$ 418K-$ 53M$ 38M
2021$ 567K-$ 51M$ 66M
2020$ 3M-$ 29M$ 109M
2019$ 31K-$ 24M$ 35M
2018$ 5M-$ 30M$ 61M
2017$ 0.00-$ 71M$ 66M
2016$ 3M-$ 102M$ 110M
2015$ 6M-$ 50M$ 172M
IPO2014$ 0.00-$ 49M$ 106M
TRVN - Trevena Inc logo

Trevena Inc fundamental performance

Between 2018 and 2023, revenue declined from $ 5M to $ 3M and net income went from -$ 30M to -$ 40M. Revenue increased in 2 of those 5 years; net income in 2.

Trevena Inc currently holds a 5-year HDB Score of 4.2 out of 10. How the HDB Score is calculated.

Membership

Explore TRVN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies